false

Harpreet Singh, MD

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.

• Read: Advancing Equity in Clinical Trials: Unpacking the FDA’s Diversity Guidance

  Clinical Trials

  Advancing Equity in Clinical Trials: Unpacking the FDA’s Diversity Guidance

  Sep 12, ‘24 | 6 min read

  • 

    Rosamund R.

  • 

    Harpreet S.

  Discover
• Read: FDA ODAC Vote: Key Changes for Perioperative Cancer Trials

  Regulatory - Oncology

  FDA ODAC Vote: Key Changes for Perioperative Cancer Trials

  Aug 01, ‘24 | 5 min read

  • 

    Harpreet Singh, MD

  Discover

Loading...

You've reach the end Back to top